Replies to post #240935 on Amarin Corp Plc (AMRN)

[ilovetech]

Hamoa, thanks again for your valuable contributions. Retire has a valid point imo. Biotech and FAANG companies are two different animals. FAANG's can advance new technologies at lightening speed, whereas, it costs billions and years to advance "a single drug" to market. Only 14% of all clinical trials go on to win FDA approval. As retire mentioned, such an enviroment ensures seeing stock manipuation. Anyone waiting around in hopes that Amarin would someday be like the FAANG companies, would wake up one morning and say, "WOW, how did life pass by so quickly?"

ILT

[dmiller]

This is what I believe as well. I believe AMRN has no plans on being bought out and plans to grow as a pharmaceutical co by adding drugs to its portfolio.

I don’t expect Amarin to be only selling icosapent ethyl in 2030 any more than I would expect Amazon to be only selling books today.

[GD]

Ask GILD and BIIB, it is not eazy to replace 10+B revenue loss,
so far, ABBV has spent more than $100B to replace HUMIRA's $20B
loss in mid of 2020s. By mid of 2020s, street will heavy discount
AMRN's stock to what ever V's total profits to net cash value,
BIIB and GILD are valued at next 10 year's net profits now,
and finally I understand why AMRN is trading around 20, street
has priced in V's next 10 year's net profits with peak sales at
$3B, it is AMRN's job to prove street is wrong, IMO.